Call for Abstract

Acadamia
  • Texas Biomedical Research Institute, USA
  • Flinders University, Australia
  • The George Washington University, USA
  • The University of Adelaide, South Australia
  • University of Michigan Medical School, USA
  • University of Louisville, USA
  • National Centre for Biotechnology, Spain
  • Pontifical Universtity of Salamanca, Spain
  • Universidade Federal de Goias, Brazil
  • JJ Strossmayer University, Croatia
  • Tehran University of Medical Sciences, Iran
  • Medical University of Vienna, Austria
  • University of Bedfordshire, UK
  • University of Oxford, UK
  • The Tazuke Kofukai Medical Research Institute, Japan
  • Pasteur Institute of Iran, Iran
  • Palacky University, Czech Republic
  • The University of Western Ontario, Canada
  • Chonbuk National University, South Korea
  •  
  •  

Business
  • Liquidia Technologies Inc., USA
  • Profectus BioSciences, Inc., USA
  • Prokarium Ltd., UK
  • FluGen Inc., USA
  • Novartis Vaccines, USA
  • Merck & Co., Inc., USA
  • Arbovax Inc., USA
  • Merck Millipore, Europe
  • Sanofi Pasteur, USA
  • UNIVAC llc, Belgium
  • Bavarian Nordic, Germany
  • VALNEVA, Austria
  • Cellular Technology Limited, USA
  • Celldex Therapeutics, USA
  • Serum Institute of India, India
  • Vedantra Pharmaceuticals, USA
  • Shanghai Zerun Biotechnology Co .,Ltd. China
  • GenPhar Inc., USA
  • InnaVirVax, USA
  • West Pharmaceutical Services, USA
  • Inovio Pharmaceuticals, USA
  • VaxInnate Corporation, USA
  • Vaxart, Inc., USA
  • Iliad Biotechnologies, Scotland
  • European Institute of Innovation and Technology, Europe
  • REIMS, France
  • International Vaccine Institute, Korea
  • Micronutrient Initiative, Bangladesh
  • Slovak Academy of Sciences, Solvakia

9th Global Summit and Expo on Vaccines & Vaccination¬† , will be organized around the theme “Prospects and Development of Prophylactic & Therapeutic Vaccines”

Vaccines 2015 is comprised of 22 tracks and 81 sessions designed to offer comprehensive sessions that address current issues in Vaccines 2015.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 5-1Innate and acquired immunity, attenuated, conjugated, toxoid, and subunit vaccines
  • Track 5-2Vaccine vectors
  • Track 5-3Live attenuated, and killed vaccines
  • Track 5-4Vaccine efficiency and effectiveness
  • Track 6-1Antiviral drug development and treatment strategies, including vaccination
  • Track 6-2Surveillance and Prevention
  • Track 6-3Antibody therapy against viruses
  • Track 7-1Response of B and T cells to the pathogens
  • Track 7-2Immune responses to vaccines and immunomodulators
  • Track 7-3Immunotherapy and chemo immunotherapy
  • Track 7-4Nano and micro particles as adjuvants and delivery systems
  • Track 7-5Macrophage model systems
  • Track 7-6Targeted delivery approaches for vaccines
  • Track 8-1Peptide vaccines, DNA vaccines, cancer vaccines
  • Track 8-2Design and development of novel vaccines
  • Track 8-3Recombinant DNA vaccine technology
  • Track 8-4Polio vaccines, HIV vaccines
  • Track 8-5Development of vaccine for human papilloma virus
  • Track 8-6Carbohydrate / polysaccharide vaccine technology
  • Track 9-1Vaccines against parasite infections
  • Track 9-2Food safety vaccines, glyco-conjugate vaccines
  • Track 9-3Emerging and re-emerging infectious disease vaccines
  • Track 9-4Pneumococcal vaccines
  • Track 9-5Rotavirus vaccines
  • Track 9-6Biomarkers in vaccines
  • Track 9-7Plant and animal based vaccines
  • Track 9-8Novel adjuvants
  • Track 9-9Advance in novel pertussis vaccines
  • Track 9-10Biodefense vaccines: The filovirus experience
  • Track 9-11Antiviral and antibacterial vaccines
  • Track 9-12Malaria vaccine
  • Track 10-1Techniques for the multi-product vaccine
  • Track 10-2Robust and reproducible manufacturing techniques
  • Track 10-3QA/QC strategies in vaccine development and production
  • Track 10-4Technological improvements for downstream processing of vaccines
  • Track 10-5Generation of vaccines using high-throughput micro bioreactors
  • Track 10-6Mechanistic basic prophylactic and therapeutic vaccines
  • Track 11-1Risk assessment and management of vaccine contamination
  • Track 11-2Case studies for HIV and tropical diseases
  • Track 11-3Personalized medicine development
  • Track 11-4Current issues in vaccine communication, safety, and health policies
  • Track 11-5Market trend and regulatory aspects of vaccine development and distribution
  • Track 11-6Epidemiological studies and scientific assessment of vaccine adverse events
  • Track 12-1Validation and optimization of treatment strategies for new targets
  • Track 12-2Vaccine trials: Clinical testing, defining efficacy endpoints, and confirmatory studies
  • Track 12-3Genetic predictors of immune response
  • Track 12-4Long term vaccine therapy for clonal exhaustion
  • Track 12-5Surveillance of vaccine preventable diseases
  • Track 12-6Vaccines: Preclinical development
  • Track 13-1Vaccine development strategies for neurodegenerative disorders
  • Track 13-2New developments in veterinary vaccines
  • Track 13-3Vaccine approaches to immunotherapy and clinical trials
  • Track 13-4Nanotechnology in vaccine delivery
  • Track 13-5Novel discoveries in allergen vaccines
  • Track 13-6Advances in the delivery methods for transcutaneous immunization
  • Track 14-1Status and impact of childhood and adolescent immunizations
  • Track 14-2Vaccination in adults and older individuals: New perspectives
  • Track 14-3Travel immunizations and safety issues
  • Track 14-4Immunization in immunocompromised patients
  • Track 14-5Challenges in implementing immunization programs and improvement strategies
  • Track 15-1Cutaneous conditions
  • Track 15-2Heart Disorders Vaccines
  • Track 15-3Plant Disorders vaccines
  • Track 15-4Animal Disorders vaccines
  • Track 15-5Valvovaginal Disorders Vaccines
  • Track 15-6neurological Disorders
  • Track 15-7Intestinal Diseases
  • Track 15-8Eye Diseases and Disorders
  • Track 15-9Endocrine Diseases vaccines
  • Track 15-10Notifiable Diseases vaccines
  • Track 16-1Cancer Cell Biology, Diagnosis and Applied Research
  • Track 16-2Anti cancer drugs and delivery
  • Track 16-3Novel Approaches to Cancer Therapeutics
  • Track 16-4Cancer Therapy and Clinical Cancer Research
  • Track 18-1Virology Vaccines
  • Track 18-2Veterinary Vaccines
  • Track 18-3Animal flu-ecology
  • Track 18-4Strategies for Developing New Antiviral Flu Drugs
  • Track 18-5 New Avenues for Influenza Control
  • Track 18-6Influenza vaccine Flu vaccine for nonhumans
  • Track 18-7Malaria vaccine